Hello and welcome back to Take Aural Lee, the podcast that allows the free movement of knowledge. Never mind Brexit, we're still here. It's been too long, glad to be back. I'm still Jamie and in this episode we're looking at anti-epileptic medication. So we've got our favourite pharmacist, Canal Gowhill is here. Hello Canal. Hello JT, what's going on, how are we doing? I'm doing well. It's weird to be with you without a glass of wine in hand. I know, very often we have a drink on the go. Well it happened, no I didn't really feel involved. I can barely talk today because I appear to have a bit of a cough.
I'm sure the listeners will be pleased that they're going to hear mostly from you. That wasn't part of the deal. That wasn't part of the deal. And it's Valentine's Day today as well. Happy Valentine's Day, JT. Oh, happy Valentine's Day. We've left our significant others at home just specifically to record this podcast. Absolutely. This is the only way I want to spend Valentine's Day. Billy Eilish's new song is out for the Bond film. It's a momentous day. Amazing. So, anti-epileptics. These are an important group of drugs. Certainly in A&E, make sure that we are prescribing these because bad things can happen. Absolutely. And they're also a drug that can complicate other things as well. They're a group of drugs, sorry. That's it. And a lot of your...
So your job is making sure patients are getting them are on the right ones as well. Yeah, so epileptic drugs in acute care. So obviously there's two situations that we'll use anti-epileptic drugs within sort of emergency department. One would be our chronic epilepsy patient or our chronic seizure patient who comes in with an unrelated problem where we're obviously treating their acute illness, but we have to be very mindful about what we're doing in terms of managing their chronic epilepsy whilst they're in the department. And the other worry obviously is the first presentation of seizures or the epileptic patient who presents in status and we have to manage them. So we actually see quite a lot of these patient subtypes and there's different ways of...
treating them in that case but they're they are very worrying they're worrying patient cohort for me and our prioritization in ed for pharmacists they fall in our sort of urgent urgent patient cohort so we go see them very quickly to make sure they don't deteriorate cool It all works quite well as it stands out. But I guess you kind of almost have to start with a bit of a definition about epilepsy and a bit of the history of seizures and things like that because it's a condition that probably still has a bit of stigma attached to it really, doesn't it? Yes, and a diagnosis that obviously has connotations with DVLA and for women, fertility and pregnancy and so on. I should point out that...
All information we're going to go through is correct at our time of recording. And guidelines are correct for Nottingham University Hospitals NHS Trust. Your other trust guidelines may vary. And I should also point out that I'm not a neurology epilepsy pharmacist. Well, I'm not a neurologist either. So together we'll get through this. And any views and opinions are the speaker's own. So whatever Carl says is his view only. So epilepsy, these are neurological conditions that...
cause seizure of some variety. Yeah. Which can be the, what I was taught was the grand mal or what we're now the generalised seizure. Yeah, I don't know if it means grand mal and petty mal anymore. It's all partial and generalised, I think, are the two sort of terms we use now. So I think the way that I think of seizures, they're not necessarily moving straight into the drugs themselves, but provoked seizures, because obviously the main pathology of epilepsy is seizures. The seizure is a symptom and epilepsy is the diagnosis, the syndrome of diagnosis, theoretically. So there's provoked seizures, I guess you'd say. So these are going to be your...
True epileptiform seizures that are provoked by, say, a space-occupying lesion, things that are by electrolyte imbalance, so hyponatremia, things like hypoglycemia. So there's lots of provoked reasons that somebody might have a seizure. Hypothermia, particularly febrile convulsions in children, this would trigger a seizure. Even stress would trigger a seizure. And these are provoked kind of things.
That's one category, and that to a certain extent is reversible. If we're reversing the cause of that, we're reversing any risk of seizures in future. Even drugs, so some illicit substances will cause seizures. Remove that problem, and then you've sorted the problem with the seizures. The other side of the coin is the non-provoked seizures, so the ones that don't have a specific cause related to them. And that's kind of where you get your epilepsy syndromes from. And that isn't really very well understood.
as it stands now so why people develop epilepsy that's unprovoked so there's talk about so basically we're talking about uncoordinated action potentials and uncoordinated and unmitigated electrical activity in the cns could be caused by a variety of things people can have genetic problems with their ion channels in the cns their cns neurons are more excitable people can have longer term electrolyte issues or head injuries things like that which will long term cause structural damage to the brain which will then cause epilepsy type syndromes so there's a lot of reasons but i think a lot of it's not really that well understood we know some genetic conditions things like I think Down syndrome are more predisposed to being epileptic, if memory serves. Yes. Angleman syndrome? Angelman syndrome? I haven't heard of that. Angleman? Angelman syndrome. Angelman syndrome. Interesting. So these are genetic conditions that predispose you to more excitation within your CNS, which will trigger a seizure. You get synchronous firing of your neurons. So move on to the drugs, as it stands, which is sort of my bag. Really quite difficult, because some of these drugs are very, very, very complicated in their mechanisms of action. And they're not...
even that well understood now, exactly how they work. They just kind of work. So the sort of history of epilepsy goes that the first sort of anti-epileptic drug, don't suppose you might know what that is? Lithium, probably? No, not lithium. Well, lithium was definitely one of the early... Lithium bromide, and bromide was actually the first anti-epileptic drug that had any real efficacy. And that was used in the 1800s. It was quite effective, actually, so they used bromide complexes, potassium bromide, and sodium bromide as sort of calming angiolitic kind of therapies. The mechanism isn't actually that well-known. They still use bromide complexes in veterinary medicine even now.
A mechanism that isn't that well understood, but we thought that bromide is a halogen ion. And one of the big mechanisms for stopping seizures is the chloride ion in the CNS on the post-synaptic cleft. And bromide kind of looks like chloride in the same charge. So you can get some bromide into the neuron and it stops the excitability. So that's been proposed. But bromide is awful stuff because it causes bromism. Bromism? I think it's called bromism. And that's a syndrome where lots of bromide causes lethargy and drowsiness. But it was used to chemically castrate homosexuals. That as well. So actually, interestingly, if memory serves, I think the original postulated reason that people would have epileptic seizures was masturbation.
Moving on. I'm pretty sure that's it. Happy Valentine's Day, everyone. For you single people out there. Absolutely. Excellent. So what was the first, was it? So the first sort of commercially available anti-epileptic drug was phenobarbitone. This is a barbiturate style drug. So that was the first one that was actually marketed as a medicine. Very powerful anti-epileptic medicine. Very good anti-epileptic medicine. It works really well. Barbiturate sort of...
gave way to phenytoin after a while, which we found out you could use phenytoin and it would start working on sodium channels, which we'll talk about in a little bit more detail in a minute. And then that gave way to probably the modern version of barbiturates, which are the benzodiazepines. So barbiturates are very similar to benzodiazepines in the way they work, but they're a lot more toxic and there's a lot more things to worry about with barbiturates than benzos. So they're not used as much in clinical practice. But you do find some older people, people in their 70s, 80s, 90s, who are diagnosed with epilepsy in their 20s and they're still on barbiturates and they're quite happy still taking them. So you will see them occasionally.
Lots of the old-fashioned drugs sort of discovered before 1980. So sort of 1950 to 1980, 1990, there was your big players within anti-epileptic drugs, the first-generation drugs. So these are your phenytoins, your barbiturates, your benzodiazepines, valproate, carbamazepine. These are the big players in anti-epileptic therapy. Really good drugs with really good efficacy. They stop seizures.
but have a lot of side effects, like a lot of nasty side effects. And they will stop seizures. They're very, very effective, but you have to go along with the adverse drug reactions. Probably 1990 onwards is where we've had the more modern second and third generation anti-epileptic agents. So these are your sort of kepras of the world, your lamotrigine, your gabapentin and progabalin, which were originally anti-epileptics, with more novel mechanisms, which are a little bit cleaner as well. So they don't cause quite as many adverse drug reactions. We do have some still, but obviously because of the way we now look at pharmacovigilance and clinical trials, it's very difficult to trial a medicine.
versus gold standard for epilepsy because it's so dangerous to have a seizure. So typically clinical trials for these newer drugs, so any anti-epileptic that's out these days, you can't just give them that versus comparing them with somebody who's on carbamazepine, for example. It's not ethical. So typically you'll give one person carbamazepine and another person carbamazepine and your new drug, and then you'll try and see if there's an additional benefit. So quite a lot of these new drugs are actually licensed for dual therapy rather than monotherapy, even though we use quite a lot of monotherapy already, so it's a bit of a misnomer as it sounds.
So yeah, lots of drugs, very, very interesting. I suppose the one thing we should touch on really quickly is the thing that I never really understood and when I had to really think about is what is the risk of having a seizure and why this is a really worrying thing to occur. So I guess you think most people when they think of seizures, they'll think of a full tonic-clonic grand mal-style seizure where you get sort of rapidly synchronised rigidity and then muscle relaxation over and over and over again and that will cause you to shake and that's your sort of classic epileptic seizure. So the one thing to consider is if anybody can have an epileptic seizure like that at any particular point in time, the worry is that that can happen. They don't have any control over their body and they could be in a very high-risk situation at that point. So if that happens to you when you're driving, if that happens to you when you're swimming or operating a really heavy machinery or something like that, you can put yourself in potentially a life-threatening situation.
And the other worry you get also is, so there's the epileptic sudden death syndrome. SUDEP. SUDEP, SUDEP. So that's literally a case where a seizure, somebody can be in status. So every year in the UK, we're kind of just looking at a bit of literature now, about a thousand people will die from that, from seizures related to epilepsy. In the UK, yeah. There's problems with things like positional asphyxia. So a status epilepticus, so a prolonged seizure, theoretically somebody could not really have any control over their muscles of their neck, and they can get themselves into a situation where they'll cut off their airway, and they can die from asphyxiation, which is a real worry. People can break bones, people can break ribs, people can dislocate bones.
really, really dangerous things that are potentially life-threatening as well. So, status epilepticus, that's when your seizure lasts longer than five minutes, a prolonged seizure. And we've agreed that that's kind of the... limit for where you're starting to look at physical damage to the body which i find quite difficult because when you speak to a bystander who may have never seen you know it's your loved one who's having a seizure who's never seen a seizure before and they'll go oh they were seizing it it felt like half an hour it probably wasn't it was probably a couple of minutes but when it's your loved one doing that it obviously feels like a long time um yeah longer than five minutes or um recurrent seizures with no recovery period in between so they remain postictal so that's that's what we mean when we say status absolutely um so a lot of people listening to this will probably learning about the pharmacology about these drugs and they may well have sort of osky scenarios where they may have to talk to a patient about some of these drugs and counsel them beforehand so shall we start having a look at some of them yeah let's go for it so i guess the first thing that we've got we have to look we have to delve a little bit into the mechanism of action of seizures themselves and this is quite difficult to do without lots of diagrams and stuff because it is incredibly complicated so consider so what we'll do is we'll break this down to simplicity i think so three abstract concepts in your head there is a
nerve fibre. We'll call it the pre-synaptic nerve fibre. There's then a gap and then there's a synapse. We'll keep it simple, man. Synapse, that's a big word. There is then a post-synaptic neuron and there's two different types of post-synaptic neurons. There is the excitatory post-synaptic neuron and there is the inhibitory post-synaptic neuron. So three players here. The accelerator and the brake. Exactly.
The whole way that you get this synchronised, out-of-control electrical disturbance in the CNS is you get a nerve impulse that comes down that first pre-synaptic neuron. It reaches the end of it, and what that then does is it causes vesicle release at the end of the neuron. So the electrical activity stops. That electrical activity stimulates neurotransmitters to go out into the synapse. And the really important one that we worry about is something called glutamate. So all this glutamate goes into the cleft. The glutamate then binds to the post-synaptic excitatory neuron.
And by doing that, it would then trigger another action potential and that continues down the rest of the nerve. So that's called the excitatory pathway. So pre-synaptor neuron, synapse fires glutamate. The glutamate binds to a receptor. The receptor is called the NDMA receptor.
And that then causes a big influx in sodium, which generates the action potential, and then we continue the electrical activity down the neuron, and it keeps going. Now, the job of the inhibitory neuron, post-cylactic neuron, is to stop that from happening. And what that does is that uses a different neurotransmitter, which goes into the cleft, to counteract some of the glutamate, to stop any overexcitation. And that's a neurotransmitter called GABA, which a lot of people might be familiar with. GABA goes into the cleft, and it doesn't bind with the NDMA receptor. It binds with the GABA receptor, which is another receptor on the excitatory.
post-synaptic cleft. And what that does is that causes a chloride ion to open up, and then you get chloride rushing in. Chloride is a negatively charged ion, and that counteracts the positively charged sodium that the glutamate does. So that controls the whole situation. So that's sort of a whistle-stop of the pharmacology between the synapses. There was lots of hand-waving there. There was. You can't see how much distinguishing I just did with my hand. That's the way I talk. I use distinguishing. So, effectively, if we consider that seizures are generated by two basic mechanisms...
One mechanism is there's too much overexcitation. So for whatever reason, there's too much sodium flying into those neurons, and there's too much glutamate being thrown into the cleft and causing the excitation on the post-synaptic neuron. So all glutamate-mediated. That's one way that we get these seizures happening. The other way is that we can also get under-inhibition from the post-synaptic cleft. So somebody's glutamate system could be absolutely fine, but if they gather...
inhibition isn't as effective as somebody else's, then they don't get enough inhibition, the break doesn't work, so to speak, and then you'll actually get these seizures being triggered. So these are the two key mechanisms of how seizures are propagated, and there are two key strategies of how we stop seizures in their path. Makes sense? Makes sense. Makes sense. It's quite tricky. So effectively, whatever we do, whatever drug we're using, we're looking to correct these kind of problems. Either by reducing over-excitation or increasing the under-inhibition. Exactly. That's our strategy. Cool, cool, cool. So...
There's three basic categories and there are more than this, but for the purposes of this podcast, all of the anti-epileptic drugs fall into three basic classes. The first class we'll talk about are drugs that modulate ion influx. And that's in the pre-synaptic and the post-synaptic excitatory neurons. So the key ion channel that causes the action potentials that gets this going is a sodium channel. So all of your ions typically have a sodium channel. It's a voltage-gated sodium channel. So once you get a stimulus, the voltage reaches a threshold. And once the neuron reaches that threshold, an action potential is generated and you get a massive firing of sodium into the cell.
Now, if you can block the sodium channel, so if you can stop sodium coming from outside of the neuron into the neuron, then you stop some of the excitation that's happening on the presynaptic neuron. And that's effectively how quite a few different drugs work. So, cum-mazapine. Sodium valproate, lamotrigine, phenytoin, topiramate and zanisamide. All of these have that kind of effect. They block the sodium channel on the pre-synaptic neuron. If you block that off, then you don't get any sodium flying in and you can't generate glutamate going into the synaptic cleft. So that works really well for sodium channels. There is another channel, the calcium channel. So there's something called the HVA calcium channel. So calcium is another positively charged ion. And again, with influx from the outside of the neuron, inside of the neuron, you get the action potential being generated. So if you can stop the calcium, again, you're stopping some of those action potentials being generated. And
There's two different groups of agents that do this. So lamotrigine, which also messes around with sodium channels, also blocks off the calcium channel. So you get kind of a dual effect with lamotrigine. And then gabapentin and pregabalin, both of those, a lot of people think that they mess around with the inhibitory pathway post-synaptically. Actually, they work on calcium channels on the presynaptic.
pre-synaptic neuron as it stands. So both of those indirectly will block calcium flying in and stop the action potential being generated in that way so you stop that electricity in its way. And they're also used in chronic pain aren't they? Yeah absolutely. Gabapentin and pregabalin, your chronic neuropathic pain. Yeah so it's exactly in the same way here so gabapentin and pregabalin though they mess around with calcium channels it's thought that those action potentials have got a place in neuropathic pain as well so triggering pain impulses. Both of those have got really really good evidence today if you can stop the calcium influx pre-synaptically you stop pain signals in the nerves which is really really effective.
There's also the post-synaptic excitatory neuron, which also has receptors in it, which causes calcium and sodium to fly in. In particular, there's something called a type 2 calcium channel. That's on the post-synaptic neuron. And valproate, zanisamide and ethosuxamide, they all have activities blocking that post-synaptically. So valproate, that's why valproate is very, very effective. It works on the pre-synaptic neuron, blocking sodium channels, and it also works post-synaptically on the calcium channel, so you get a kind of double effect from it. So effectively, all of those are stopping the electrical impulse through the nerve, and electricity is your problem to start with anyway.
So that's kind of your modulation of ion influx, and they're your key players with that class. The other main mechanism that you'll get, we talked about the inhibitory pathways, so that's making more of that inhibition, so propagating GABA. So these drugs are just making more GABA to make that chloride channel have more chloride flowing into the postsynaptic neuron, and therefore you're stopping the positivity and generating the action potential. So again, you've got to have this image in your head now, that on that postsynaptic cleft we have this chloride ion channel, so a chloride channel. And on that has a bunch of different receptors that will open it up. So one of them is the GABA receptor. So that's where the actual neurotransmitter will come in and it will bind to it and it'll open the chloride channel. And then you'll get chloride that will fly in and stop dampening down any of that electrical activity. And that's all natural.
That chloride ion channel will also have a benzodiazepine receptor. So we use our benzodiazepines, so diazepam, virazepam, midazolam, all of those will bind to that postsynaptic chloride channel, open it up and allow more chloride in, which then dampens everything down. There's equally another one for barbiturates. Barbiturates will bind to that receptor, open up the chloride, and it will allow chloride to go back in. Typically, benzos and barbiturates, they're our go-tos for status epilepticus as our first line, aren't they? So our protocol in ED for status epilepticus would be four milligrams of IV virazepam, because you're really...
getting lots of benzo into that receptor to allow loads of chloride to fly in and stop propagation of the seizures. So it's a really, really effective, very potent mechanism for that. That being said, if you open up too much chloride and you don't allow any kind of excitation, then you end up with people going really drowsy and really lethargic, which is our classic side effect for benzodiazepines and barbiturines. Losing the desire to breathe. Losing the desire to breathe, indeed. So there's a couple of other ones as well. So there's a couple of drugs called Vigabatrin and Tigabine. I have not heard of those. Yeah, so these are more novel. And what they do is one of them, the Tigabine, that basically causes the...
gabaminergic inhibitory neuron to recycle more GABA. So basically it potentiates more GABA to be spit out into the synapse, and then that therefore allows more chloride to go into the post-inhibitory neuron. And then the other one, the bigger veteran, also stops GABA in the synaptic cleft to be reuptaken, so it allows more of the GABA to be sitting there around in the cleft, so more of it is activated. Because all of these neurotransmitters, they eventually just get reuptaken after a little while, so you just have more of it flying around in there. So that's kind of how our gabaminergic type agents will work. All of them are potentiating that chloride ion.
And then the third basic one are kind of the miscellaneous group to a certain extent. So they're the novel mechanisms. And the main novel mechanism that we have, the one to really point out, would be a very, very popular one called levotiracetam. So Keppra, levotiracetam. Very pleased it gets changed to Keppra. I think they went with a very basic name just because it is that hard. It took me years to learn how to say levotiracetam, literally. And it's got a slightly novel mechanism. It doesn't work on iron channels, and it doesn't work on GABA. What it does is, we talked originally about that action potential getting to the end of the...
presynaptic neuron and then the glutamate comes out. Now if you look in a little bit more detail about how the glutamate gets released, it actually gets released through a vesicle that comes out of the postsynaptic cleft. which is stimulated through calcium channels. What Keppra does is it stops that vesicle coming out of the neuron. So it effectively stops any glutamate from getting into the synapse. And therefore, if you haven't got any glutamate in the cleft, you don't get any endoma action, and therefore you don't get propagation of the electrical activity. So Keppra is one that's got a novel mechanism. There are a few other drugs that have got other novel mechanisms, but I think Keppra is the only one that's really worth talking about without getting incredibly in-depth.
So that's kind of a whistle-stop about your three key mechanisms of action on how we're looking at CG. Cool. Right, so let's start going through some of those in turn then. So let's start first with probably most commonly used ones, sodium valparate. Sodium valparate, yeah. Also known as epilim. Yep, that's right. So the other thing I forgot to mention actually in the previous bit. So valparate has actually been shown to have some...
inhibitory effects on GABA as well so we talked about valparite having effects on sodium channels we talked about having effects on calcium channels so it works on that ion channel way but actually it's been postulated to have some effect on that chloride ion as well so actually it potentiates chloride coming in as well so it's got multiple mechanisms of action which makes it a really really powerful anti-epileptic drug and it's actually first line recommended by NICE for quite a lot of different seizure types so tonic-clonic absence, partial, you can use valprate actually quite successfully for quite a lot of different seizure profiles. And it's actually now unlicensed even on our status protocol, isn't it? Yeah, so sodium valprate here is now the... it used to be phenytoin, was our first line of treatment for stasis epilepticus, whereas now we've changed it to sodium valprate. Yeah, so status refractory to benzos that we can't stop with lorazepam, sodium valprate is now our first line. And you're quite right, it used to be phenytoin, but we've moved to valprate now because...
it is a bit safer, we think, all around than phenytoin is. So I usually think of alpinephrine as one of the broadest spectrum anti-epileptic drugs, if you want to give it a sort of antibiotic kind of spin. And it's got very good use in status epilepticus as well. Now, it does have its problems. And the one that's probably really important to remember is it's about its teratnogenic potential. So valproate in ladies of childbearing potential you have to be very careful with. A known teratnogenic can cause spina bifida and other problems in an unborn fetus. And there's been a lot of cases of children being born with deformities off the back of their mothers being put on valproate. So in ladies of childbearing potential, if we're using valproate, then they need to potentially be on a pregnancy prevention scheme.
we need to be given the pregnancy test or we need to think about switching that therapy to something else that's more suitable for pregnancy. So it's a really important one. We had a massive drive in Nottingham when this came out from the MHRA to get the neurologist to review their patients for childbearing potential. So that's a fairly big thing then if you were preparing for an OSCE or just revising in general, you know, sodium valparate if you're having to have that conversation. and your patient is female, this is the conversation to have. You definitely don't want to miss that one. That's probably a critical fail or something if you don't mention that one, I would have thought. So very good stuff. It comes in a variety of different formulations. So it comes as an IV injection, which is what we use for status or people that can't swallow because they're unwell. It comes in tablets, comes in liquid, comes in little sachets. There's loads of different ways you can get it in, so it makes it a very robust drug pharmaceutically for us as well. All of those preparations are pretty much interchangeable. So the dose, the frequency is all pretty much the same. You don't have to mess around too much with the dose, and that saves us a lot of time and effort, particularly in ED when we've got people who are flat but we need to give them IV.
it has got a bit of an idiosyncratic adverse drug profile. So it's been associated particularly acutely with pancreatitis, so it can cause an acute pancreatitis. So if you've got your person with a lipase through the sky who's just been started on valproate for whatever it might be, you can consider that as a potential cause of it. It can cause a hyperammonemia, so it naturally raises your ammonia levels through a very complicated mechanism, which I'm not going to try and explain. Also, equally with the pancreatitis through the same mechanism, you can get an acute hepatitis off the back of it. It can cause, is it called hirsutism? Hirsutism. Hirsutism, so increased hair growth.
And it can also cause your blood disgrasias, so neutropenias, thrombocytopenias, things like this, particularly in the initial stages of treatment. So always want to keep an eye out. You do have to make sure that people on Valparate have got their bloods monitored six monthly to yearly, depending on their profile. We do sometimes do blood levels with epilim. It's not brilliantly correlated to efficacy, plasma levels, but it is useful if you suspect toxic-type reactions. Your classic toxic reaction for valprate is sort of drowsiness, lethargy, ataxia, these sort of type symptoms that you'd be worried about a toxic reaction. But generally, it's pretty well-tolerated. Cool.
So good drug, really good drug, Alfred. The main thing you always have to remember is pregnancy for that one. That's the thing that always worries us. On to phenytoin. Phenytoin. So phenytoin, as you said, was our previous first line. One of the oldest of the anti-epileptic drugs. As you've said. Actually a very powerful anti-arrhythmic as well. Which is why every patient has gone monitoring. That's the one, exactly. And this is actually the reason why a lot of trusts now have gone away from phenytoin as their first line for status. Very effective drug. It's an incredibly powerful sodium channel blocker in the CNS. But equally, because it's...
pretty non-specific for cardiac sodium channels, you can get nasty arrhythmias off the back of it. You can put people into blocks, put people into BT, all these sort of things. So it's quite a worrying one. So particularly if you're giving it IV, you have to give it relatively slowly and you have to monitor people's ECG and BP when you're giving it. There has been some catastrophic events with them when people have been given phenytoin too quickly in particular and it's caused what's called deaths in the past. So it's a bit of a worrying drug in that.
It's got a very narrow therapeutic index, and it is typically a very difficult drug to use therapeutically. So it suffers from something called saturation kinetics, which is something that really worries us as nerdy pharmacists. So basically, it's a drug that doesn't have a linear correlation with its plasma concentration. So to give you a concept, if you give somebody 5mg of morphine, they'll have X effect. If you give them 10mg of morphine, you can typically expect that effect to be doubled. That's called linear kinetics. Phenotoin, you can give someone...
for example, a gram of phenytoin, and it will be effective, efficacious. If you gave them 1.1 grams, they'd be pushed into an outrageously toxic level because it has an exponential curve in terms of its plasma concentrations. It's got an incredible amount of interactions because it's processed heavily by the liver, so it interacts with a lot of different drugs, and it's one of our classic enzyme inhibitors. So it typically will sort of potentiate metabolism of other drugs, particularly things like doax and anticoagulants. You have to be really careful with phenytoin. It will just pretty much obliterate their plasma concentrations.
And it's very highly albumin bound. So it's one of these drugs that sticks to albumin for dear life. And there have been a couple of cases. I've been involved in a couple of cases where we have older patients who have been established on phenytoin who have not been eating. You know, they've got older, they've got more frail, they've lost weight. Their albumin tends to plummet, but their dose of phenytoin stays the same because their albumin plummets.
their free phenytoin levels increase and they go toxic on the same dose. And it's an incredibly difficult situation to diagnose and manage because you have to lower the dose, then you tend to get seizures. Very, very difficult one to deal with. It also has a lot of adverse drug reactions. So some quite classic ones, which are gingival hyperplasia. So it causes swelling of the gums, can cause tooth problems. So people are typically predisposed to more dental issues, being on phenytoin. It can have quite nasty CNS toxic effects, so it'll cause a nystagmus, diplopia, ataxia, even at relatively therapeutic concentrations.
So you have to be very careful with toxic phenytoin reactions because it interacts with everything. On top of that, we said that valproate was brilliant because all the different preparations are pretty much exactly the same. Phenytoin, if you change a capsule to a tablet, to a liquid, to an IV, you pretty much have to use a different dose for every single one of them because the bioavailability is so different depending on what you give. So long story short, phenytoin, great drug in terms of stopping seizures, but incredibly difficult to use therapeutically for patients. So typically these days it's not used much anymore. Very few people go on it. Cool.
And then on to number three. On to the next one. What have we got next? Which is carbamazepine. Tegretol carbamazepine. I should be taking the brand names, really. A lot of people know their anti-epileptics through brand names. They're the companies that have marketed these drugs.
They've spent a fortune on basically making you associate the drug with the brand. So we talked about valproate first time, that's epilim. So a lot of patients will say I take epilim, that is sodium valproate. Do you know phenytoin? Phenytoin's much harder. No. Epineutin. Yeah, that one's not as famous, granted, but epineutin is the brand name for it. Carbamazepine is tegritol. Quite a famous brand name. Again, you'll get people that always...
We'll always use that. Again, another broad-spectrum agent that works on sodium channels. It's a little bit more useful, particularly in your partial seizures. So it's one that, for some reason, has particularly good evidence for complex partial seizures and your petty mile-style seizures. That being said, it's very poor for absence seizures. So for the seizures where you get those sort of momentary lapses where they go in and out of consciousness, tegritol tends to make that worse.
For some reason, I don't actually know why, but it tends to make that worse. The main thing to worry about with carbamazepine is it's probably the worst in terms of interaction profile with other drugs. It's, again, a very powerful enzyme inducer. So it will drop the plasma concentration of a lot of other drugs. And in particular, we talked about anticoagulants. So if you're ever starting a drug with somebody who's already on carbamazepine, do an interaction check on the BNF because it interacts with a lot of different things and they can be quite clinically significant.
So you have to be very, very careful with that one. It's a drug that's classically associated with Stephen Johnson syndrome. Toxic epidermal necrolysis. So that's this nasty skin sloughing reaction. We had a case with it, I think, last year. One of our ACPs dealt with the case of Stephen Johnson. It wasn't Carmaskin, it was something else, actually, but that's one that we do worry about. Classically, in your... I think it's your Korean and your Chinese ethnic origin.
I'm not 100% sure. There's subtypes of ethnic people that are more likely to get Stephen Johnson syndrome on carbamazepine. So you effectively never use carbamazepine in people from sort of the Far East. So you're, I think it's Korea, I think it's Malaysia, these kind of areas. There's actually a list of that. I'll double check it. Google that for me. And the other one is it's classically associated with hyponatremia.
So patients on carbamazepine will tend to develop a chronic hyponatremia. Typically asymptomatic, but if it gets quite bad, then they can end up with symptomatic hyponatremia off the back of it. So those are sort of our older type drugs, I guess you'd say. So they're the ones with really good efficacy, but like we said earlier, they've got loads of adverse drug reactions that we have to worry about. They're difficult to use. So we'll move on to a couple, probably the two of our most commonly used of the newer generation drugs. So the first one is levotoracetam, Keppra.
So I always call it levotiracetam. Levotiracetam. That's not wrong. Levotiracetam. Keppra. As I tweeted you, it's just Keppra. Just call it Keppra. Just call it Keppra. I say levotiracetam, but you're not wrong, as it stands anyway. Thank you. So as we said, good option and nice guidance for partial seizures, but we can also use that for secondary generalisation as well, and it is pretty damn good. It's got actually a very good evidence base for status epilepticus as well. Quite broad spectrum agent, so now we've put it in our status guideline, second line to valprate.
And it's typically got a much lower interaction profile. And there's the Eclipse trial that was comparing Keppra to phenytoin in children's state epilepsies, which there was a previous podcast of that. That's it. I'll link back to that one. So typically much lower problems in terms of adverse drug reactions and interactions. It's a cleaner drug, typically. The one that you do worry about with Keppra is it's renally excreted. So patients with CKD are more likely to get the toxic effects of levotoracetam, and you have to be more careful with the doses for that. But you'll actually see a lot of people started on levotoracetam as their first-line agent, just because it's very well-tolerated, typically.
And the other one of the newer agents to talk about is Lamotrigine. So we talked earlier that that... Lamictal. Lamictal. Lamictal is the brand name. We talked earlier that that works on multiple different ion influxes, so it's got broad spectrum agents. It's another one that unfortunately is associated with Stephen Johnson syndrome. Same population of patients to worry about there. But again, it's got probably the lowest of the adverse drug reactions. So...
Typically, it's one that you always start very slow. So you start at about 25mg once a day and you can build all the way up to 200, 300mg twice a day, so quite a lot of it. But you have to get there very slowly. And if you go slow, then you tend to find lower incidence of adverse drug effects. The only problem with Lamotrid is you can only give it orally.
So if your patient is flat and you need to get stuff in, then you can't really use Lamotrigine, whereas Keppra is useful because it's got the intravenous root as well and it's just pound to pound the same. So those are a couple of the newer agents which are really, really useful. Cool. They're probably the key ones to talk about. I suppose the other ones to talk about are the benzodiazepines, very briefly. So very few people these days take regular benzodiazepines. Yeah, these are more of the rescue, you know, children will have, say, a reptile.
midazolam or something. Yeah, so we'd have rexaldazepam, we'd have buccal midazolam, typically. Yeah, or we'll use either as we talked about in status, yeah. Yeah, so typically now, yeah, we reserve these for status rather than prophylaxis because they've got too many adverse drug effects associated with them. And they're very drowsy and they affect people's sort of life, so we don't really do it. They're addictive, people get tolerance. The only real time you see patients on regular benzodiazepines is you see people on clobazam and clonazepam. Clobazam, typically, they might take it short term if they've had a bout of seizures because they tend to be high risk for having burner seizures in the post-ictal period.
You see people on five to seven days of clobazam after an episode of seizures. And clonazepam can be used more regularly because it's less than 18. So they're both useful benzodiazepines for longer-term use. Your daozepams, your lorazepams, your midazolams tend to be reserved just for status-type situations. From my own experience, the clonazepam tends to be a, this patient has had a first seizure, I talk to neurology, yes, we'll see them in clinic, I'll start them on a short course of this in the meantime before we see them, or add this to their regime because they've had a seizure despite being on treatment. And there's a couple of different things there. So number one, like you said, there's the risk that...
They've had a seizure and there's something going on that's predisposing them to a higher frequency of seizures. So they're getting a little bit of extra cover during that period. And there's also a little bit about safety netting. So actually, if a neurologist wants you to bring somebody back or wants to investigate, they'd actually much rather them not have a seizure during that time period. Yes. And they'd prefer to over-treat a little bit during that time period. So there's a couple of different bits with that. There's really good evidence of clobazine. There's a couple of good papers I've read previously about using short-term clobazine on top of whatever their normal regime might be. Excellent. So good stuff. Bits of housekeeping before we... Yeah, so just thinking sort of the audience here about things that you'll have to consider. So I remember when I was in pharmacy school, one of the classic ones we got is...
a patient comes and sees you it's more of a GP situation but it could well be an ED situation I have had one of these they've said they're having greater frequency of seizures, even though their medicines haven't changed and they've been seizure-free for years and years and years, but they've noticed the way their tablets look have changed. So they've got a different brand? Potentially, or a different manufacturer. And this is a problem. So we have to remember that people take anti-epileptics for effectively their entire lives. This is a lifelong treatment. And this is why adverse drug reactions for people on anti-epileptics, you have to think very carefully about. Because this is something that somebody's not taking for a week or a month. They're taking this for the rest of their life and it really will impact their ability to do things. So adverse drug reactions are a big thing.
The plasma concentrations of some of these drugs we've already talked about can be really, really narrow. Different drugs, different brands of drugs, different manufacturers of drugs can have ever so slightly different amounts pound for pound of drug in them. A 100mg phenytoin tablet made by Accord might have 100mg in it. A 100mg tablet of phenytoin made by whoever else could have 97mg in it. That's within our tolerances. That 3mg in somebody taking phenytoin can actually make a massive difference.
As a result of that, the MHRA actually released a list of anti-epileptic agents which should not be substituted. So these people must have the same brand and ideally the same manufacturer all the time. And typically the ones you should never switch are phenytoin, phenobarbitoin if they're still on it, primidone, which is actually a pro-drug of phenobarbital, and tegritol, carbamazepine. So the MHRA typically advises that those drugs are not switched because there's a high risk that if they are switched, they'll potentially precipitate seizures from them or you can send someone toxic with them. There's then a group that we should try and keep consistent but are less worrying. So that would encompass things like valproate.
Things like Lamotrigine, Tepiramate, Clobazam, a couple of other ones as well. And they're ones, if we have to, we can switch them, but otherwise we should typically try and keep people on the same dose, same brand. And then there's one where it doesn't really make a difference. So that's things like Keppra, Levitaracetam. Typically they say it's very unlikely to cause a problem if they change brands. Gabapentin, Pregabalin, and Lecosamide as well. All of those are very unlikely to cause any problems if you switch brands. So if you do get a patient who says to you, oh, I've changed brands, and I think procedures have been playing up, we might want to think about getting them back onto what they were on originally. Cool.
Thank you very much, Canard. No problem, you're most welcome. There's a lot there that we've covered. That's excellent. Any good resources to look at? So the Epilepsy Society. There's actually a lot of very useful stuff for healthcare professionals on that. If you're here at this Trust, then the Status Epilepticus Guidelines are very, very good, if you can get your hands on them. All Trusts will have a Status Guideline. And there is the British Society of Neurologists, Neurology Society, I think it's called. They have epilepsy guidelines, particularly around initiating different agents and monitoring.
And then there's NICE on epilepsy. And which agency should consider first line, the monitoring, these sort of things as well. Brilliant. And we will link all that on the website, takeorally.com. This podcast will be out on Apple Podcasts, SoundCloud, and Spotify. We'll put together an infographic, which you can find on Instagram. Might need that infographic. Takeorally's also on, so you can find Takeorally on Twitter, Instagram, and Facebook as well. Thank you very much, Canal. JT, it's been a pleasure. Happy Valentine's Day again. Happy Valentine's Day. Happy Valentine's Day, everybody. Happy Valentine's Day, everyone. Much love.